Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer

The aim of the study was to investigate the effect of FOLFOX4 regimen combined with Brucea javanica emulsion on the content of serum vascular endothelial growth factor (VEGF) in patients with gastric cancer, and to evaluate the efficacy of FOLFOX4 regimen combined with Brucea javanica emulsion on gastric cancer. A total of 60 patients with gastric ulcer were selected as the normal group, and another 150 patients with gastric cancer were randomly divided into two groups, of which 75 patients with gastric cancer treated with FOLFOX4 regimen after operation were selected as the control group and another 75 patients with gastric cancer treated with FOLFOX4 regimen combined with Brucea javanica emulsion after operation were selected as the experimental group. The serum VEGF levels of patients in the different groups before operation, after chemotherapy for 3 times and at 1 and 3 months after chemotherapy were compared via enzyme-linked immunosorbent assay. The content of serum VEGF in patients with gastric cancer before operation was significantly higher than that in the normal group (P<0.05). After administration of chemotherapy 3 times, the content of serum VEGF in the control group had no significant difference from that in the experimental group (P>0.05). Additionally, at 1 and 3 months after chemotherapy, the content of serum VEGF of patients in the experimental group were significantly lower than those in the control group (P<0.05). The results showed that FOLFOX4 regimen combined with Brucea javanica emulsion can significantly reduce the level of serum VEGF in patients with gastric cancer, and has a certain effect in reducing the postoperative recurrence rate of gastric cancer and improving the effect of chemotherapy.